Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 7;12(4):55.
doi: 10.1038/s41408-022-00654-0.

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3"

K H Begna  1 , X Xu  2 , N Gangat  3 , H Alkhateeb  3 , M M Patnaik  3 , A Al-Kali  3 , M A Elliott  3 , W J Hogan  3 , M R Litzow  3 , C C Hook  3 , A P Wolanskyj-Spinner  3 , A Mangaonkar  3 , R He  2 , A Pardanani  3 , M Shah  3 , R P Ketterling  2 , A Tefferi  3
Affiliations

Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with "7+3"

K H Begna et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Overall and Relpase Free Survival in 70 patients with Core-Binding factor AML.
a Overall Survival Stratified by Age; b Overall Survival Stratified by Relapse; c Relapse free survival stratified by Gender; d Relapse free survival stratified by primary vs. therapy-related.
See this image and copyright information in PMC

References

    1. Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17:3767–75. doi: 10.1200/JCO.1999.17.12.3767. - DOI - PubMed
    1. Byrd JC, Ruppert AS, Mrozek K, Carroll AJ, Edwards CG, Arthur DC, et al. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461. J Clin Oncol. 2004;22:1087–94. doi: 10.1200/JCO.2004.07.012. - DOI - PubMed
    1. Appelbaum FR, Kopecky KJ, Tallman MS, Slovak ML, Gundacker HM, Kim HT, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135:165–73. doi: 10.1111/j.1365-2141.2006.06276.x. - DOI - PubMed
    1. Borthakur G, Kantarjian H, Wang X, Plunkett WK, Jr, Gandhi VV, Faderl S, et al. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008;113:3181–5. doi: 10.1002/cncr.23927. - DOI - PMC - PubMed
    1. Gottardi M, Mosna F, de Angeli S, Papayannidis C, Candoni A, Clavio M, et al. Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia. Hematol Rep. 2017;9:7029. doi: 10.4081/hr.2017.7028. - DOI - PMC - PubMed

Substances